Multiparametric Cardiac MRI in Oncological Patients Under Chimeric Antigen Receptor T-Cell Therapy
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
Recently chimeric antigen receptor (CAR) T-cell therapy, a new class of chemo therapy, has gained regulatory approval for the treatment of diseases such as B-cell lymphoma. Known side effects include cytokine release syndrome, which has been described to lead to myocarditis, but larger studies exploring this relationship are currently lacking. In this prospective study, the investigators aim to explore the potential effects of CAR T-cell therapy using cardiac MRI on the heart.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:
• Patients undergoing CAR T-cell therapy
• Consent to participate in study
Locations
Other Locations
Germany
University Hospital Bonn
RECRUITING
Bonn
Contact Information
Primary
Julian Luetkens, MD
julian.luetkens@ukbonn.de
+49 228 287 11831
Time Frame
Start Date: 2022-05-16
Estimated Completion Date: 2025-12
Participants
Target number of participants: 60
Treatments
CAR T-cell Therapy Group
Hematooncological patients undergoing CAR T-cell therapy with Tisagenlecleucel, Axicabtagen-ciloleucel, Idecabtagen-vicleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel or Ciltacabtagene Autoleucel (dosages, frequency and duration to be determined by the treating oncologist).
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Bonn